A randomized Investigator-sponsored trial of mirvetuximab in the in patients with recurrent platinum-sensitive ovarian cancer
Latest Information Update: 02 Mar 2022
At a glance
- Drugs Mirvetuximab soravtansine (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
Most Recent Events
- 02 Mar 2022 New trial record